fbpx

molecules of the month

WF-47-JS03

RET kinase inhibitor

orally efficacious in XG but narrow TI

from data mining of internal matter and opt.

ACS Med. Chem. Lett. Feb. 12, 2020

Novartis (GNF), San Diego, CA

WF-47-JS03
1 min read

(Novartis (GNF) oral in vivo RET kinase inhibitor)


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: